Osteogenesis imperfecta

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Wednesday, March 9, 2022
Hypertensive emergency, Senior, Maintenance, Private Securities Litigation Reform Act, Compliance, Cytopenia, Company, Partnership, Workforce, Research, U.S. Securities and Exchange Commission, KROS, Ruxolitinib, MDS, Anemia, Intellectual property, Privacy, GLOBE, Bone loss, Patient, Security (finance), Disorder, Osteoporosis, COVID-19, Growth, Therapy, Osteogenesis imperfecta, SEC, Thrombocytopenia, Lists of diseases, Program, Biotechnology, Part, Corporation, Microdeletion syndrome, Protein, Pharmaceutical industry, Management, Airline

In exchange, Keros received an upfront net payment of $18.0 million in January 2022, extending expected cash runway into the first quarter of 2024.

Key Points: 
  • In exchange, Keros received an upfront net payment of $18.0 million in January 2022, extending expected cash runway into the first quarter of 2024.
  • Strengthened leadership with key appointment: In February 2022, Keros appointed Christopher Rovaldi as Chief Operating Officer.
  • The revenue in the year ended December 31, 2021 was primarily related to the license agreement Keros entered into with Hansoh.
  • Keros cash and cash equivalents as of December 31, 2021 was $230.0 million compared to $265.9 million as of December 31, 2020.

Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022

Retrieved on: 
Thursday, March 3, 2022
Monaco Age Oncologie, Georgetown University, Therapy, OI, Patient, NIH, Investor, Forward-looking statement, National, Security (finance), Respiratory tract, Annual report, U.S. Securities and Exchange Commission, Oncology, Osteogenesis imperfecta, Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Phase II, Form 6-K, Hematopoietic stem cell transplantation, Webcast, National Institutes of Health, Company, COVID-19, Degenerative disease, National Cancer Institute, Neoplasm, Division, Program, Ovarian cancer, Review, AATD, R, MD, GLOBE, NASDAQ, NCI, Pharmaceutical industry, Medicine

LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D Day on Monday, March 14, 2022, to review the Companys alvelestat (MPH966) program.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a virtual R&D Day on Monday, March 14, 2022, to review the Companys alvelestat (MPH966) program.
  • Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases.
  • The Companys partner, Ultragenyx Pharmaceutical, Inc., is expected to initiate a pivotal pediatric study for setrusumab in OI in H1 2022.
  • The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Therapy, FTSE, Board, Monaco Age Oncologie, Degenerative disease, NASDAQ, Security (finance), Annual report, CFO, Form 6-K, Neoplasm, Sanofi, Industry, Company, OI, Audit, U.S. Securities and Exchange Commission, FCA, AATD, KPMG, Vulnerability and Risk Committee, Trinity College, Cancer, Audit committee, Patient, CTA, Forward-looking statement, Osteogenesis imperfecta, Ovarian cancer, Pharmaceutical industry, Management, Vectura Group

LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Companys Board of Directors, effective immediately.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Companys Board of Directors, effective immediately.
  • Ms. Hyland joins Mereos Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space.
  • We are very excited to welcome someone with Annes level of operational and board experience to our Board, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • I am honored to be joining the Mereo Board at such a pivotal time for the Company, said Ms. Hyland.

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Friday, February 11, 2022
Cytopenia, NASDAQ, Patient, Bone loss, Hypertensive emergency, Ruxolitinib, KROS, Microdeletion syndrome, Osteogenesis imperfecta, Lists of diseases, Osteoporosis, Disorder, Protein, Therapy, Maintenance, Growth, Anemia, Keros, Conference, Investor, GLOBE, Thrombocytopenia, Pharmaceutical industry

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.

Key Points: 
  • LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.
  • The fireside chat presentation will be webcast live at https://wsw.com/webcast/svbleerink67/register.aspx?conf=svbleerink67&pag... and archived in the Investors section of the Keros website at https://ir.kerostx.com/.
  • A replay will be available for 90 days following the conclusion of the event.
  • Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need.

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Retrieved on: 
Thursday, February 10, 2022
OI, Regeneron Pharmaceuticals, Pivotal, Evinacumab, Osteogenesis imperfecta, Patient, European Economic Area, Adult, ANGPTL3, Ageing, Diet, Pharmaceutical industry, Ultragenyx

NOVATO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2021 and reaffirmed its financial guidance for 2022.

Key Points: 
  • The first patients have been dosed in the Phase 3 study of DTX401 following an approximate 4- to 8-week baseline screening period.
  • Ultragenyx expects to initiate the Phase 3 eNH3ance study of DTX301 in patients with OTC in the first half of 2022.
  • ET to discuss the fourth quarter and year 2021 financial results and provide a corporate update.
  • Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyxs Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/).

Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 10, 2022
NASDAQ, GLOBE, Osteogenesis imperfecta, Form 6-K, Forward-looking statement, Degenerative disease, Ovarian cancer, U.S. Securities and Exchange Commission, AATD, Neoplasm, Conference, Monaco Age Oncologie, Investor, Company, Annual report, Safety, Security (finance), Therapy, Webcast, OI, Eastern Time Zone, Pharmaceutical industry

LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 8:00am Eastern Time.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 8:00am Eastern Time.
  • Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases.
  • The Company has developed a portfolio of six clinical stage product candidates.
  • The Companys partner, Ultragenyx Pharmaceutical, Inc., is expected to initiate a pivotal pediatric study for setrusumab in OI in H1 2022.

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

Retrieved on: 
Monday, January 31, 2022
Growth, Leadership, Disorder, Patient, Therapy, Microdeletion syndrome, University, Hematology, Ruxolitinib, Bone loss, Anemia, Biotechnology, Hypertensive emergency, LLC, Osteogenesis imperfecta, Program, Microbiology, Cytopenia, Thrombocytopenia, GLOBE, KROS, Program management, Osteoporosis, Senior, Protein, Lists of diseases, Cubist Pharmaceuticals, Maintenance, Pharmaceutical industry

LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022.

Key Points: 
  • LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the appointment of Christopher Rovaldi as Keros' Chief Operating Officer, effective as of February 1, 2022.
  • Mr. Rovaldi previously served as a consultant to Keros.
  • We are excited to welcome Mr. Rovaldi to the executive team as Chief Operating Officer, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros.
  • This addition allows us to benefit from his leadership and successful track record within the biopharmaceutical industry.

Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting

Retrieved on: 
Monday, December 13, 2021
Osteogenesis imperfecta, Monaco Age Oncologie, Population, UPMC Hillman Cancer Center, NASDAQ, Graft-versus-host disease, Neoplasm, National, Therapy, Form 6-K, Patient, Senior, Pulmonary fibrosis, OI, Forward-looking statement, ULN, Scar, Biomarker, U.S. Securities and Exchange Commission, Safety, Security (finance), AATD, GVHD, GLOBE, ASH, SEM, Society, UPMC, Bronchiole, Center, Zymosan, Degenerative disease, GA, NCI, National Cancer Institute, Elastin, Company, Principal, Annual report, Hematopoietic stem cell transplantation, Clinical trial, University of Pittsburgh, Mortality, Ovarian cancer, University, Disease, Pharmaceutical industry, BOS, MD

These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.

Key Points: 
  • These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Six patients had stable disease (2 with an improvement of 9% in FEV1), while 4 had improved symptoms at end of study.
  • The potential of alvelestat to impact the progression of lung fibrosis in this patient population is also exciting and warrants further evaluation.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

Retrieved on: 
Monday, December 13, 2021
Therapy, Osteogenesis imperfecta, NMPA, Disorder, U.S. Securities and Exchange Commission, IIA, Intellectual property, Protein, MDS, Degenerative disease, Growth, CNS, Private Securities Litigation Reform Act, EGFR, Haematopoiesis, Bone loss, COVID-19, KROS, Osteoporosis, Acute leukemia, CML, SEC, Thrombocytopenia, PAH, Anemia, Cytopenia, BCR-ABL, Microdeletion syndrome, Research, Patient, Security (finance), Infection, Program, Lists of diseases, GLOBE, NSCLC, Maintenance, Partnership, FC, Diabetes, Ruxolitinib, Central nervous system, Pharmaceutical industry

Under the terms of the agreement, Hansoh will obtain an exclusive license from Keros to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau.

Key Points: 
  • Under the terms of the agreement, Hansoh will obtain an exclusive license from Keros to develop, manufacture and commercialize KER-050 within the territories of mainland China, Hong Kong, and Macau.
  • We look forward to working with Hansoh in China, to unlock the potential of KER-050 for patients in China, said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros.
  • Yuan Sun, Executive Director of Hansoh Pharma, added, We are excited to partner with Keros, a leader in understanding the role of the Transforming Growth Factor-Beta family of proteins.
  • Under the terms of the agreement, Hansoh is responsible for the development, regulatory approval and commercialization of KER-050 in mainland China, Hong Kong, and Macau.

Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors

Retrieved on: 
Tuesday, November 30, 2021
EON, Patient, Security (finance), Clinical Ovarian Cancer & Other Gynecologic Malignancies, Cervical cancer, International, Ovarian cancer, Form 6-K, Safety, PD-L1, Domestic, Nivolumab, Annual report, Forward-looking statement, Company, Neoplasm, Population, PVR, Monaco Age Oncologie, Monroe Dunaway Anderson, ID, U.S. Securities and Exchange Commission, Therapy, Uveal melanoma, Telephone, Investor, AATD, GLOBE, OI, Osteogenesis imperfecta, IDMC, Webcast, NASDAQ, Degenerative disease, Pharmaceutical industry

LONDON and REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors.

Key Points: 
  • These early results from the ACTIVATE study are highly encouraging and support the further study of etigilimab in combination with an anti-PD-1 antibody in solid tumor types, especially in gynecologic malignancies, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • The ACTIVATE study aims to enroll approximately 125 patients across seven parallel cohorts.
  • The ovarian cohort in ACTIVATE has now crossed futility for expansion into the second stage of the study (IDMC review pending).
  • The combination of etigilimab and nivolumab has been safe and well tolerated, with no new safety signals.